Skip to main content
RFL
NYSE Life Sciences

Rafael Holdings Posts $29.6M FY2026 Loss, $22.1M Cash, Confirms NDA Filing

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Real Estate Services Stocks · Real Estate
Sentiment info
Negative
Importance info
7
Price
$1.14
Mkt Cap
$62.934M
52W Low
$1.12
52W High
$3.96
52W Position info
1.8% above low
Off High info
71% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

RFL is trading near its 52-week low of $1.12 (1.8% above the low) on light trading volume (0.2× avg).

Summary

Rafael Holdings reported a $29.6 million net loss for fiscal 2026, with $22.1 million of cash left at July 31, 2026, down from $52.8 million a year earlier, and confirmed its NDA submission for remibetadex in Niemann-Pick Disease Type C.


Key Events · Earnings and Guidance · RFL

  • FY2026 Net Loss of $29.6 Million

    Full-year net loss attributable to Rafael Holdings was $29.6 million, or $0.58 per share, versus $30.5 million, or $1.04 per share, a year earlier. The fourth quarter alone lost $9.2 million, or $0.18 per share.

  • Cash Fell to $22.1 Million

    Cash and cash equivalents stood at $22.1 million at July 31, 2026, down from $52.8 million at July 31, 2025 — a $30.7 million decline over the year against a $29.6 million net loss.

  • R&D Spending Jumped on Cyclo Consolidation

    Full-year R&D rose to $24.3 million from $12.8 million, primarily a $13.4 million increase in Cyclo's R&D following its March 2025 consolidation. G&A fell to $9.7 million from $13.8 million.

  • Going-Concern Risk Flagged

    The release's forward-looking statements cite 'our need for additional financing and the substantial doubt about our ability to continue as a going concern.'


Analysis · RFL · Life Sciences

The NDA submission was already public this morning, so the real news here is the fiscal year-end balance sheet: cash fell to $22.1 million from $52.8 million a year earlier, against a full-year net loss of $29.6 million. That burn rate relative to remaining cash is the central issue — the company's own forward-looking statements flag substantial doubt about its ability to continue as a going concern, and management is pointing to a Priority Review Voucher as a potential source of non-dilutive capital. The next hard checkpoint is the FDA's 60-day decision from receipt on whether to file the NDA and grant Priority Review.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RFL was trading at $1.14 on NYSE in the Life Sciences sector, with a market capitalization of approximately $62.9M. The 52-week trading range was $1.12 to $3.96. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RFL - Latest Insights

RFL
Oct 29, 2026, 11:35 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $1.20
Real-time Price: $1.09 info
Change: -$0.105 (-9%) info
Market Cap: $57.937M info
RFL
Oct 29, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.14
Real-time Price: $1.09 info
Change: -$0.050 (-4%) info
Market Cap: $57.937M info
RFL
Sep 30, 2026, 7:23 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.32
Real-time Price: $1.09 info
Change: -$0.230 (-17%) info
Market Cap: $57.937M info
RFL
Sep 30, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.24
Real-time Price: $1.09 info
Change: -$0.150 (-12%) info
Market Cap: $57.937M info
RFL
Jul 08, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.57
Real-time Price: $1.09 info
Change: -$1.48 (-58%) info
Market Cap: $57.937M info